Helen Vålerhaugen

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1

Giovanni Cazzaniga, Vincent H. J. van der Velden, J M Cayuela et al. · Leukemia · 2019 · 75 citations · Full text

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +10

Infused CD34⁺ cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B‐cell lymphoma and follicular lymphoma grade 3 treated with high‐dose therapy

Anne Kirsti Blystad, Jan Delabie, Stein Kvaløy et al. · British Journal of Haematology · 2004 · 56 citations · Full text

Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia

Signe Modvig, Hans O. Madsen, Sanna Siitonen et al. · Leukemia · 2018 · 56 citations · Full text

Hematological Malignancy, Flow Cytometry, Lymphoid Neoplasia +15

Peripheral T-cell lymphoma with involvement of the expanded mantle zone

Ida Münster Ikonomou, Anne Tierens, Hege Vangstein Aamot et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2006 · 37 citations

Lymphoid Neoplasia, Peripheral T-cell Lymphoma, Surgical Pathology +8

Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia

Kristian Juul-Dam, Hans Beier Ommen, Charlotte Guldborg Nyvold et al. · British Journal of Haematology · 2020 · 33 citations · Full text